Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sharon Sacham"'
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Supplemental Figure 1: Response to immunization is only modestly affected by selinexor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7e3dd2782c79ebaa858be1024365729
https://doi.org/10.1158/1535-7163.22509346
https://doi.org/10.1158/1535-7163.22509346
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Supplemental Figure 3: Degranulation of effector CD8 T cells is affected by selinexor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a22bc7dcb83589955473e577e58b61a
https://doi.org/10.1158/1535-7163.22509340.v1
https://doi.org/10.1158/1535-7163.22509340.v1
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Supplemental Figure 2: IFNγ secretion is impaired by selinexor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1240f94ccb7d588d494dd8aa1380214
https://doi.org/10.1158/1535-7163.22509343.v1
https://doi.org/10.1158/1535-7163.22509343.v1
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Selinexor (KPT-330) is a first-in-class nuclear transport inhibitor currently in clinical trials as an anticancer agent. To determine how selinexor might affect antitumor immunity, we analyzed immune homeostasis in mice treated with selinexor and fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ca42473c520b40f0072488fdabd409
https://doi.org/10.1158/1535-7163.c.6539275.v1
https://doi.org/10.1158/1535-7163.c.6539275.v1
Autor:
Annemiek M E Walenkamp, Andrew B. Lassman, Christopher J. Walker, Andrea Califano, Yao Shen, Leah Henegar, Patrick Y. Wen, Sharon Tamir, Kai Li, Martin J. van den Bent, Morten Mau-Sørensen, Hua Chang, Michael Kauffman, Yosef Landesman, Mariano J. Alvarez, Adam L. Green, Sharon Sacham, Scott R. Plotkin
Publikováno v:
Clin Cancer Res
Clinical Cancer Research, 28(3), 452-460. American Association for Cancer Research Inc.
Clinical Cancer Research, 28(3). AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28(3), 452-460. American Association for Cancer Research Inc.
Clinical Cancer Research, 28(3). AMER ASSOC CANCER RESEARCH
Purpose:Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various solid and hematologic tumors. We assessed intratumoral penetration, safety, and efficacy of selinexor monotherapy for recurrent glioblastoma.Patients and M
Autor:
Sharon Sacham, Stephanie K. Dougan, Romy C de Vries, Boris Klebanov, Trinayan Kashyap, Mariah M. Servos, Paul M Tyler, Michael Dougan, Yosef Landesman
Publikováno v:
Molecular cancer therapeutics. 16(3)
Selinexor (KPT-330) is a first-in-class nuclear transport inhibitor currently in clinical trials as an anticancer agent. To determine how selinexor might affect antitumor immunity, we analyzed immune homeostasis in mice treated with selinexor and fou